Girritinib (Segatan) applicable population and clinical recommended use guidelines

Gilteritinib (Gilteritinib) is an oral FLT3 inhibitor, mainly used to treat individuals with FLT3 mutations in patients with acute myeloid leukemia (AML). FLT3Mutation is one of the most common genetic abnormalities in AML, accounting for about one-third of all patients, and is often associated with poor prognosis. Giritinib can selectively inhibit the activity of FLT3 receptor tyrosine kinase, thereby blocking abnormal signaling pathways, inhibiting leukemia cell proliferation and promoting apoptosis, providing an important treatment option for this type of high-risk patients.

Clinically, giritinib is mainly suitable for patients with relapsed or refractory (R/R) AML, especially FLT3-ITD or FLT3-TKD mutation-positive patients. For newly diagnosed AML patients, if they have high-risk mutations and are well tolerated, they can also be used in combination with chemotherapy under the guidance of a doctor. The guideline recommends genetic testing before treatment to clarify the type and load level of FLT3 mutation, so as to optimize the treatment plan and ensure that giritinib can exert the greatest efficacy in the most suitable patient group.

The recommended clinical use guidelines for giritinib emphasize individualized dosing and regular monitoring. The conventionally recommended starting dose for adult patients is 120 mg once daily, which needs to be adjusted according to liver and kidney function, drug tolerance and hematological indicators. During the treatment process, hematological indicators, liver and kidney function, and electrocardiographic indicators such as QT interval should be regularly evaluated to detect adverse reactions and adjust the dose in a timely manner. Some patients may develop anemia, thrombocytopenia, or abnormal liver function, and intervention is required based on clinical symptoms.

In addition, giritinib can be used in combination with other chemotherapy drugs or targeted drugs to improve the response rate and prolong progression-free survival (PFS). Special attention should be paid to drug interactions and superimposed toxicity during combined treatment to ensure treatment safety. Overall, giritinib is suitable for FLT3 mutation-positive relapsed or refractory AML patients and has significant clinical value in the era of precision molecular targeted therapy. During use, patients should strictly follow the doctor's instructions, follow up regularly, and make individualized adjustments combined with genetic testing and efficacy evaluation to achieve the best treatment effect.

Reference materials:https://www.drugs.com/

xa0